Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program

Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program

Source: 
Endpoints
snippet: 

In a significant setback, Vivek Ramaswamy-backed Arbutus Biopharma is ceasing the development of its experimental hepatitis B therapy, after two healthy volunteers contracted serious liver infection in an early-stage trial.